For immunotherapy to play a meaningful role in HR+/HER2 negative early breast cancer, a breast cancer subtype where most patients are cured with standard therapy, it will need to significantly increase the fraction of cured patients without disproportionately causing serious and/or long-term immune toxicity. This evidence concerns the gene ERBB2 and breast cancer.